A research study in South Africa further evaluating Johnson & Johnson’s COVID-19 vaccine in the field will resume on Wednesday, the health ministry said after the study was paused over rare cases of blood clots in people given the vaccine.
During the pause, it had been established that there is a one in a million chance of getting a clot after the vaccine, regulators across the world have recommended the continued use of J&J’s shot, the ministry said.
Local regulator SAHPRA, the South African Medical Research Council and the health ministry have worked to ensure there is intensified pre-vaccination assessment and post-vaccination monitoring when the J&J study resumes, it added.
A research study in South Africa further evaluating Johnson & Johnson’s COVID-19 vaccine in the field will resume on Wednesday, the health ministry said after the study was paused over rare cases of blood clots in people given the vaccine.
During the pause, it had been established that there is a one in a million chance of getting a clot after the vaccine, regulators across the world have recommended the continued use of J&J’s shot, the ministry said.
Local regulator SAHPRA, the South African Medical Research Council and the health ministry have worked to ensure there is intensified pre-vaccination assessment and post-vaccination monitoring when the J&J study resumes, it added.
A research study in South Africa further evaluating Johnson & Johnson’s COVID-19 vaccine in the field will resume on Wednesday, the health ministry said after the study was paused over rare cases of blood clots in people given the vaccine.
During the pause, it had been established that there is a one in a million chance of getting a clot after the vaccine, regulators across the world have recommended the continued use of J&J’s shot, the ministry said.
Local regulator SAHPRA, the South African Medical Research Council and the health ministry have worked to ensure there is intensified pre-vaccination assessment and post-vaccination monitoring when the J&J study resumes, it added.
A research study in South Africa further evaluating Johnson & Johnson’s COVID-19 vaccine in the field will resume on Wednesday, the health ministry said after the study was paused over rare cases of blood clots in people given the vaccine.
During the pause, it had been established that there is a one in a million chance of getting a clot after the vaccine, regulators across the world have recommended the continued use of J&J’s shot, the ministry said.
Local regulator SAHPRA, the South African Medical Research Council and the health ministry have worked to ensure there is intensified pre-vaccination assessment and post-vaccination monitoring when the J&J study resumes, it added.
A research study in South Africa further evaluating Johnson & Johnson’s COVID-19 vaccine in the field will resume on Wednesday, the health ministry said after the study was paused over rare cases of blood clots in people given the vaccine.
During the pause, it had been established that there is a one in a million chance of getting a clot after the vaccine, regulators across the world have recommended the continued use of J&J’s shot, the ministry said.
Local regulator SAHPRA, the South African Medical Research Council and the health ministry have worked to ensure there is intensified pre-vaccination assessment and post-vaccination monitoring when the J&J study resumes, it added.
A research study in South Africa further evaluating Johnson & Johnson’s COVID-19 vaccine in the field will resume on Wednesday, the health ministry said after the study was paused over rare cases of blood clots in people given the vaccine.
During the pause, it had been established that there is a one in a million chance of getting a clot after the vaccine, regulators across the world have recommended the continued use of J&J’s shot, the ministry said.
Local regulator SAHPRA, the South African Medical Research Council and the health ministry have worked to ensure there is intensified pre-vaccination assessment and post-vaccination monitoring when the J&J study resumes, it added.
A research study in South Africa further evaluating Johnson & Johnson’s COVID-19 vaccine in the field will resume on Wednesday, the health ministry said after the study was paused over rare cases of blood clots in people given the vaccine.
During the pause, it had been established that there is a one in a million chance of getting a clot after the vaccine, regulators across the world have recommended the continued use of J&J’s shot, the ministry said.
Local regulator SAHPRA, the South African Medical Research Council and the health ministry have worked to ensure there is intensified pre-vaccination assessment and post-vaccination monitoring when the J&J study resumes, it added.
A research study in South Africa further evaluating Johnson & Johnson’s COVID-19 vaccine in the field will resume on Wednesday, the health ministry said after the study was paused over rare cases of blood clots in people given the vaccine.
During the pause, it had been established that there is a one in a million chance of getting a clot after the vaccine, regulators across the world have recommended the continued use of J&J’s shot, the ministry said.
Local regulator SAHPRA, the South African Medical Research Council and the health ministry have worked to ensure there is intensified pre-vaccination assessment and post-vaccination monitoring when the J&J study resumes, it added.
Related posts:
Novavax begins mid-stage study of COVID-19 vaccine in S. Africa
Trump wants Pompeo to study ‘killing of farmers’ in South Africa
COVID-19: South Africa to import 1.5m doses of AstraZeneca vaccine
Covid-19: South Africa approves Pfizer vaccine for children aged 5-11 years
Research Union urges President Buhari to sign Research Bill
China denies claim of trying to copy U.S vaccine research
Study shows ‘significant decline’ in genital mutilation rates in girls in Africa
Study estimates 190,000 people killed in South Sudan’s civil war
